Finally, sequential measurement of these AKI biomarkers (e.g., daily, weekly) or other AKI biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding proteins) may reflect the dynamic aspects of clinical diseases and thus provide superior information on mortality risk. Here, GOT2 is linked to acute kidney injury.